Search results
Results from the WOW.Com Content Network
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS).
Catalyst Brands LLC is a parent company formed in 2025 by the merger of SPARC Group and JCPenney. [ 1 ] [ 2 ] SPARC Group brands include Aéropostale , Brooks Brothers , Eddie Bauer , Forever 21 , Lucky Brand Jeans , and Nautica .
See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page. This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources .
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. [8] In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. [8] It is given by injection into a vein. [8]
Aquaphor is a brand of over-the-counter (OTC) skin care ointments manufactured by Beiersdorf Inc., an affiliate of Beiersdorf AG. Aquaphor is offered in four product ranges. There are two skin protectant ointments: [ 1 ] Aquaphor Original Ointment, used as a compounding agent; [ 2 ] [ 3 ] and Aquaphor Advanced Therapy Healing Ointment, sold in ...
The US Food and Drug Administration (FDA) granted the application priority review, in addition to fast track, breakthrough therapy, and orphan drug designations. The drug's manufacturer Vertex Pharmaceuticals will receive a rare pediatric disease priority review voucher for having developed this therapy.
Tisagenlecleucel is indicated for the treatment of those under 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse; or adults with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma ...
Pegunigalsidase alfa, sold under the brand name Elfabrio, is an enzyme replacement therapy for the treatment of Fabry disease. [2] [4] It is a recombinant human α-galactosidase-A. [4] It is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme. [2] The most common side effects are infusion-related reactions, hypersensitivity and ...